Results 81 to 90 of about 5,494 (193)

An Integrative Strategy Delineates Modular Metabolic Remodeling and Potential Therapeutic Targets Across Metabolic Diseases

Advanced Science, Volume 13, Issue 52, 18 September 2026.
An integrative single‐cell atlas across multiple metabolic diseases reveals coordinated metabolic modules and disease‐shared versus disease‐specific pathway activities. By systematically comparing scoring strategies, a robust RankAve framework is established. Coupled with network analysis and drug‐target prediction, this resource uncovers cross‐disease
Kuan Yang, Congxue Hu, Hang Zhao, Xiao Peng, Yiming Yan, Jiasi Wang, Wenqi Jiang, Depeng Mu, Yan Cao, Xia Li, Yunpeng Zhang   +10 more
wiley   +1 more source

Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease

Molecules
The most prevalent chronic neurodegenerative illness in the world is Alzheimer’s disease (AD). It results in mental symptoms including behavioral abnormalities and cognitive impairment, which have a substantial financial and psychological impact on the ...
Amin Mahmood Thawabteh, Aseel Wasel Ghanem, Sara AbuMadi, Dania Thaher, Weam Jaghama, Donia Karaman, Rafik Karaman   +6 more
doaj   +1 more source

Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA review

Alzheimer’s Research & Therapy, 2023
Key points of disagreement between the aducanumab FDA statistical review, which had primarily negative conclusions, and the clinical review, which had primarily positive conclusions, were investigated.
Samuel P. Dickson, Sean Hennessey, Jessie Nicodemus Johnson, Newman Knowlton, Suzanne B. Hendrix   +4 more
doaj   +1 more source

Enhancing early Alzheimer's disease clinical trials through prognostic score covariate adjustment

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract INTRODUCTION A prognostic score (PS) summarizes a patient's expected disease progression and can increase the statistical efficiency of clinical trials when included as an analysis covariate. METHODS We pooled patient data from observational studies and randomized trials for early Alzheimer's disease (AD) and trained PS candidates to predict ...
Bruno T. Scodari, Roland Brown, Xiaotong Jiang, Changyu Shen, Kyle Ferber, Shuang Wu, Feng Gao, Szofia Bullain, Brian Millen   +8 more
wiley   +1 more source

Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy

Frontiers in Radiology
Alzheimer's Disease (AD) is a leading cause of morbidity. Management of AD has traditionally been aimed at symptom relief rather than disease modification.
Houman Sotoudeh, Mohammadreza Alizadeh, Ramin Shahidi, Parnian Shobeiri, Zahra Saadatpour, C. Austin Wheeler, Marissa Natelson Love, Manoj Tanwar   +7 more
doaj   +1 more source

Therapeutic Potential of Oxiracetam in Neurocognitive Disorders: A Narrative Review

Brain and Behavior, Volume 16, Issue 9, September 2026.
ABSTRACT Purpose: Cognitive impairment is a growing global health concern associated with aging, neurodegenerative diseases, stroke, and traumatic brain injury. Existing pharmacological treatments, including cholinesterase inhibitors and memantine, provide limited and variable benefits.
Hafsa Ali, Syeda Maliha, Sundas Ishtiaq, Omer Al‐Karawi, Mohammed Hammad Jaber Amin   +4 more
wiley   +1 more source

Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

, 2017
This corrects the article DOI: 10.1038/nature21361. Erratum for An intermediate-mass black hole in the centre of the globular cluster 47 Tucanae. [Nature. 2017] The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Grimm, Jan, Nitsch, Roger M, Sandrock, Alfred, et al, Hock, Christoph, Sevigny, Jeff, Chiao, Ping, Ping Chiao, Roger M. Nitsch, Tianle Chen, Alfred Sandrock, Mahin Arastu, Yan Ling, James Ferrero, Fang Qian, Stephen Salloway, Sowmya Chollate, Omar Quintero-Monzon, Jeff Sevigny, H. Moore Arnold, Robert H. Scannevin, Kenneth Rhodes, Robert Dunstan, John O’Gorman, Paul H. Weinreb, Leslie Williams, Mingwei Li, Christoph Hock, Thierry Bussière, Marcel Maier, Melanie S. Brennan, Alvydas Mikulskis, Jan Grimm, Thomas Engber, Yaming Hang   +34 more
core   +1 more source

Multimerization of a rationally designed nanobody for enhanced avidity toward Aβ42 oligomers

Protein Science, Volume 35, Issue 9, September 2026.
Abstract Alzheimer's disease affects tens of millions of people worldwide and is associated with the self‐assembly of the Aβ42 peptide into amyloid aggregates. Among the species formed during this process, soluble oligomeric intermediates are the most closely linked to neurotoxicity and are therefore an attractive target for both therapeutic and ...
Magdalena Nowinska, Elijah Suh, Casey Mogilevsky, Michele Vendruscolo   +3 more
wiley   +1 more source

Novel Therapeutic Insights Into Alzheimer's Disease: Glymphatic System and Meningeal Lymphatic Vessels

Aging Cell, Volume 25, Issue 9, September 2026.
The identification of the glymphatic system (GS) and meningeal lymphatic vessels (mLVs) challenges the century‐old “immune‐privileged” dogma of the central nervous system (CNS), establishing a critical mechanistic link between impaired waste clearance (Aβ/tau) and the pathogenesis of Alzheimer's disease (AD).
Bingbing Song, Wei Wang, Siqi Liu, Xi Jin, Yan Qi, Mingquan Li, Dongjie Yue, Yu Liu, Xiangqi Li, Lei Yin, Lina Feng   +10 more
wiley   +1 more source

Comparative efficacy and safety of symptomatic therapy and disease-modifying therapy for Alzheimer’s disease: a systematic review and network meta-analysis

Frontiers in Neuroscience
BackgroundThe management of Alzheimer’s disease has shifted toward disease-modifying therapies aimed at delaying disease progression rather than focusing solely on symptomatic treatment.
Shiyu Liu, Shiyu Liu, Min Zhao, Min Zhao, Yuan Liu, Yuan Liu, Xin Yang, Xin Yang, Huayu Yan, Huayu Yan, Hongcai Xu, Hongcai Xu, Yabo Wu, Yabo Wu, Yumin Xu, Yumin Xu   +15 more
doaj   +1 more source